Pin your most used calculators here by clicking the star in the dropdown.
Lymphoma (DLBCL) Prognosis Panel
U/L
U/L
Clinical Context & Background
This panel computes both the Classic International Prognostic Index (IPI) and the NCCN-IPI for Diffuse Large B-Cell Lymphoma (DLBCL).
Classic IPI: The historical standard for risk stratification.
NCCN-IPI: An enhanced model developed in the Rituximab era. It refines risk stratification by weighting age and LDH more heavily and identifying specific high-risk extranodal sites (Bone Marrow, CNS, Liver/GI, Lung).
Reference Data
| Risk Group | Classic IPI (5y OS) | NCCN-IPI (5y OS) |
|---|---|---|
| Low | 0-1 (73%) | 0-1 (96%) |
| Low-Intermediate | 2 (51%) | 2-3 (82%) |
| High-Intermediate | 3 (43%) | 4-5 (64%) |
| High | 4-5 (26%) | 6-8 (33%) |
Related Tools
Evidence-based oncology decision support. Verify with clinical guidelines.